Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1

Neurosurgery

Volumn 65, Issue SUPPL. 4, 2009, Pages

  Karabatsou, Konstantina ^a   Kiehl, Tim Rasmus ^b   Wilson, David M ^b   Hendler, Aaron ^b   Guha, Abhijit ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

18Fluorodeoxyglucosepositron emission tomography computed tomography; Malignant peripheral nerve sheath tumors; Neurofibromatosis 1

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; NEUROFIBROMA; NEUROFIBROMATOSIS; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; EVALUATION; METHODOLOGY; MIDDLE AGED; NERVE SHEATH TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; SCINTISCANNING;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMA; NEUROFIBROMATOSIS 1; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 70350645518     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000337597.18599.D3     Document Type: Article

References (37)

1. Angelov L, Davis A, Bell R, Guha A: Management of neurogenic sarcomas: University of Toronto experience. Adv Clin Neurosci 7:357-374, 1997.
2. Angelov L, Davis A, O'Sullivan B, Bell R, Guha, A: Neurogenic sarcomas: Experience at the University of Toronto. Neurosurgery 43:56-65, 1998.
3. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A: Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer 107:1065-1074, 2006.
4. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS: Accuracy of whole body dual-modality fluorine- 18-2-fluoro-2-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 22:4357-4368, 2004.
5. Bastiaannet E, Groen H, Jager, PL, Cobben DC, van der Graaf WT, Vaalburg WT, Hoekstra HJ: The value of FDG-PET in the detection, grading, and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30:83-101, 2003.
6. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R: A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379, 2000.
7. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF: Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging 33:428-432, 2006.
8. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, Lehnert T: Evaluation of F18-deoxuglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumors. Eur J Surg Oncol 29:536-541, 2003.
9. Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN, Littrup PJ, Taub JW, Getzen TM: Retroperitoneal malignant peripheral nerve sheath tumor: Evaluation with serial FDG-PET. Clin Nucl Med 29:415-418, 2004.
10. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ: Diagnosis of soft tissue masses with MRI imaging: Can benign masses be differentiated from malignant ones? Radiology 185:581-586, 1992.
11. Delbeke D: Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med 4:591-603, 1999.
12. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP: Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329, 1982.
13. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T: Dynamic PET 18F-FDG studies in patients with primary and recurrent soft tissue sarcomas: Impact on diagnosis and correlation with grading. J Nucl Med 42:713-720, 2001.
14. Doorn PF, Molenaar WM, Buter J, Hoekstra HJ: Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 21:78-82, 1995.
15. Ducatman B, Scheithauer BW, Piepgras DG, Reiman H, Ilstrup DM: Malig - nant peripheral nerve sheath tumors: A clinicopathological study of 120 cases. Cancer 57:2006-2021, 1986.
16. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A: Malig - nant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314, 2002.
17. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, Bingham J: Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumors arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 68:353-357, 2000.
18. Friedrich RE, Kluwe L, Fünsterer C, Mautner VF: Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): Diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res 25:1699-1702, 2005.
19. Griffeth LK, Dehdashti F, Mcguire AH, Mcguire DJ, Perry DJ, Moerlein SM, Siegel BA: PET evaluation of soft tissue masses with fluorine-18fluoro-2- deoxy-D-glucose. Radiology 182:185-194, 1992.
20. Hruban RH, Shiu MH, Senie RT, Woodruff JM: Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 66:1253-1265, 1990.
21. Iagaru A, Quon A, McDougall IR, Gambhir SS: F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med 31:754-760, 2006.
22. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF: Association of local recurrence with survival in extremity soft tissue sarcoma. J Clin Oncol 15:646-652, 1997. (Pubitemid 27074234)
23. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, Mckee PH, Smith MA: Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 86:550-556, 1999.
24. Mautner VF, Hartman M, Kluwe L, Friedrich RE, Funstener C: MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48:160-165, 2006.
25. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, Koops HS, Vaalburg W: Fluorine-18-fluorodeoxyglucose PET imaging of soft tissue sarcoma. J Nucl Med 37:257-261, 1996.
26. Otsuka H, Graham MM, Kubo A, Nishitani H: FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: A case report. Ann Nucl Med 19:55-58, 2005.
27. Ramanathan RC, Thomas M: Malignant peripheral nerve sheath tumors associated with von Recklinghausen's neurofibromatosis. Eur J Surg Oncol 25:190-193, 1999.
28. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T, Herfarth C: Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 231:380-386, 2000.
29. Solomon SB, Semih Dogan A, Nicol TL, Campbell JN, Pomper MG: Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 26:525-528, 2001.
30. Suh JS, Abenoza P, Galloway HR, Everson LI, Griffiths HJ: Peripheral (extracranial) nerve tumors: Correlation of MR imaging and histologic findings. Radiology 183:341-346, 1992.
31. Townsend DW, Beyer T: A combined PET/CT scanner: The path to true image fusion. Br J Radiol 75:S24-S30, 2002.
32. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM: Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205-211, 2005.
33. Weiss SW, Goldblum JR: Benign tumors of peripheral nerves, in Weiss SW, Goldblum JR (eds): Enzinger and Weiss's Soft Tissue Tumor. St. Louis, Mosby, 2001, ed 4, pp 1137-1142.
34. Weiss SW, Goldblum JR: Malignant tumors of peripheral nerves, in Weiss SW, Goldblum JR (eds): Enzinger and Weiss's Soft Tissue Tumor. St. Louis, Mosby, 2001, ed 4, pp 1209-1263.
35. Wong WW, Hirose T, Scheithauer BW, Schild S, Gunderson LL: Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42:351-360, 1998.
36. Woodruff JM, Kourea HP, Louis DN, Scheithauer BW: Malignant peripheral nerve sheath tumor (MPNST), in Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System. Lyon, IARC Press, 2000, pp 172-174.
37. Zadeh G, Guha A: The neurosurgical implications of neurofibromatosis, in Batjer HH, Loftus C (eds): Textbook of Neurological Surgery. Philadelphia, Lippincott Williams & Wilkins, 2003, vol 2, pp 1515-1522.